Who is sponsoring NCT05237349?

NCT05237349 is sponsored by Liangjun Zhu M.M..

What drugs are being tested in NCT05237349?

Interventions in NCT05237349: Envafolimab, Oxaliplatin, S1.

What condition does NCT05237349 study?

NCT05237349 studies Metastatic or Recurrent Gastric Adenocarcinoma.

Is NCT05237349 still recruiting?

NCT05237349 is currently status unknown. Last updated 5 January 2024.

Last reviewed 2024-01-05 · How we verify

NCT05237349

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Status unknown Phase 2 Last updated 5 January 2024

What this trial tests

Phase 2 trial testing Envafolimab in Metastatic or Recurrent Gastric Adenocarcinoma in 38 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	Liangjun Zhu M.M.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	1 March 2022
Primary completion	1 December 2024
Estimated completion	1 December 2024
Sites	1 location across China

Drugs / interventions tested

Envafolimab — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
S1 — full drug profile →

Conditions studied

Metastatic or Recurrent Gastric Adenocarcinoma — all drugs for Metastatic or Recurrent Gastric Adenocarcinoma →

Sponsor

Liangjun Zhu M.M.

Who can join

Adults 18 to 75, any sex, with Metastatic or Recurrent Gastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to investigate the efficacy and safety of Envafolimab combined with chemotherapy in the treatment of metastatic or recurrent gastric adenocarcinoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Envafolimab

Trials testing the same drug.

NCT06959693 — A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients Wit · Phase 2, PHASE3 · not yet recruiting
NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
NCT07260305 — A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolima · Phase 1 · recruiting
NCT06618391 — Local Injection and Systemic Therapy in the Treatment of NSCLC. · Phase 2 · not yet recruiting
NCT06663007 — RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05237349 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Liangjun Zhu M.M.
Last refreshed: 5 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05237349.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing